The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer

We aimed at investigating the prognostic significance of a novel immune marker, PIV and PILE score (a score composite from PIV, LDH and ECOG PS), in patients with HCC in a single center.

120 patients who met the criteria were included. PIV and PILE at the time of diagnosis were computed retrospectively. For PIV, the median value of 286.15 was taken as the cut-off. While <286.15 was considered low, ≥286.15 was considered high PIV. The PILE score included PIV (< median vs. ≥ median), lactate dehydrogenase level (

The median first-line PFS and OS in the low PIV group were 10 months (95% CI: 7.77-12.22) and 18 months (95% CI: 10.66-25.33), respectively. The PFS and OS in the high PIV group were 3 months (95% CI: 1.49-4.51) and 4 months (95% CI: 1.47-6.52), respectively (for PFS p=0.001, for OS p<0.001). In the low-risk (0-1) PILE score group, the median first line PFS and OS were 8 months (95% CI: 6.49-9.50) and 17 months (95% CI: 8.19-25.80), respectively. The high-risk (2-3) group, PFS and OS were 3 months (95% CI: 0-5.99), and 3 months (95% CI: 1.02-4.97), respectively (for PFS p=0.02, for OS p<0.001). In multivariate Cox regression analysis, PIV (HR: 1.81, 95% CI: 1.11-2.93, p=0.016) and ECOG PS (HR: 0.72, 95% CI: 1.34-3.19, p=0.01) were independent risk factors for OS.

The findings suggest that PIV and PILE score could be used as a prognostic biomarker at the time of diagnosis in patients with HCC. With prospective studies confirming these data, PIV and PILE can be used as a potential standard marker in HCC.